Catalyst Wire Dossier Catalyst Wire Dossier

DG3173

· Aspireo Pharmaceuticals Limited
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for DG3173, covering 2014-08-15 to 2018-02-15. Get the full timeline:

Most recent: Clinical Trial Update: The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics [Phase 2]

See pricing